The Aaron's Company, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas A. Lindsay
- Full Time Employees
- 9,071
- Sector
- Industrials
- Industry
- Rental & Leasing Services
- Address
- 400 Galleria Parkway SE Atlanta GA United States of America 30339-3182
- IPO Date
- Nov 25, 2020
- CIK
- 0001821393
- Website
- aarons.com
- Similar Companies
- Business
- The Aaron's Company, Inc. is a technology-enabled, omnichannel provider specializing in lease-to-own and retail purchase solutions primarily for furniture, consumer electronics, home appliances, computers, fitness equipment, tools, and outdoor merchandise. Founded in 1955 and headquartered in Atlanta, Georgia, the company operates a broad network of stores across the United States and Canada under its key brands including Aaron’s, BrandsMart U.S.A., BrandsMart Leasing, and Woodhaven. Its product offerings comprise name brand furniture, electronics, appliances, and related home goods tailored to moderate-income consumers through flexible payment plans combining in-store and digital commerce platforms. In recent major developments, The Aaron's Company completed a $504 million acquisition by IQVentures Holdings, a fintech organization, in October 2024, transitioning the company to a private ownership structure. This strategic partnership aims to accelerate Aaron’s omnichannel strategy and enhance operational efficiency, building on the company’s transformation efforts over previous years. Additionally, Aaron’s continues to expand its GenNext store format, which redefines the physical retail experience by integrating spacious showrooms, advanced technology-enabled shopping, expanded product assortments, and innovative operating models. In 2023 alone, Aaron's converted or opened 38 new GenNext stores, bringing the total to 249, a key initiative to improve customer engagement and drive future growth. The Aaron's Company serves a competitive market through a diversified business model combining lease ownership and retail sales, with a strong presence in the U.S. and Canada. Its operations include company-operated and franchised stores supported by a robust e-commerce platform, targeting a broad demographic of consumers seeking affordable home furnishings and electronics with flexible financial solutions. The acquisition by IQVentures represents a significant strategic shift, leveraging fintech expertise to further integrate financial technology innovation with its retail and leasing services for enhanced customer experience and long-term growth. Overall, The Aaron's Company, Inc. continues to lead in the lease-to-own retail sector by offering a wide spectrum of durable home products and services, backed by recent investments in technology, store modernization, and ownership changes that position it for ongoing expansion and operational excellence in North America.
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Aton Appoints Oscar Amigo as Chief Operating Officer of its Subsidiary, Aton Mining Inc.
Aton Reports Further High Grade Diamond Drilling Results From Abu Marawat, Including 33.86 g/t Gold and 419 g/t Silver Over 2.5 Metres From the Fin Vein, and 44.59 g/t Gold and 103 g/t Silver Over 1.6 Metres From the J Vein
Aton Reports Further Diamond Drilling Results From Abu Marawat, Including 8.52 g/t Gold and 88.7 g/t Silver Over 15.4 Metres, and 6.06 g/t Gold and 59.6 g/t Silver Over 17.3 Metres
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting